Pharmacologic Therapy of Type 2 Diabetes

Medical Clinics of North America

Volumn 100, Issue 4, 2016, Pages 647-663

  Wright, Jennifer J ^a   Tylee, Tracy S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

DPP 4 inhibitor; GLP 1 analog; Insulin; Metformin; SGLT 2 inhibitor; Sulfonylurea; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

ARTHRALGIA; BALANITIS; BLADDER CANCER; BLOATING; DIARRHEA; DRUG CONTRAINDICATION; DRUG COST; DRUG RESPONSE; DRUG SAFETY; GERIATRIC PATIENT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PATIENT SELECTION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; VASCULAR DISEASE; VULVOVAGINITIS; AGING; AGONISTS; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION ROUTE; ECONOMICS; GLUCOSE BLOOD LEVEL; RENAL INSUFFICIENCY;

AGING; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION ROUTES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84971440716     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.03.014     Document Type: Review

References (63)

1. 2014 National Diabetes Statistics Report. 2014. Available at: . Accessed September 1, 2015. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html.
2. Zhuo X., Zhang P., Barker L., et al. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes Care 2014, 37(9):2557-2564.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
4. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865.
6. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
7. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
8. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
9. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
10. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013, 19(2):327-336.
11. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310(6972):83-88.
12. Inzucchi S.E., Lipska K.J., Mayo H., et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014, 312(24):2668-2675.
13. Salpeter S.R., Greyber E., Pasternak G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, (4). CD002967.
14. Zhang X., Harmsen W.S., Mettler T.A., et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014, 60(6):2008-2016.
15. Moreno G., Mangione C.M., Kimbro L., et al. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J Am Geriatr Soc 2013, 61(11):2020-2026.
16. de Jager J., Kooy A., Lehert P., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010, 340:c2181.
17. Phung O.J., Schwartzman E., Allen R.W., et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013, 30(10):1160-1171.
18. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147(6):386-399.
19. Bennett W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154(9):602-613.
20. Zhang Y., Hong J., Chi J., et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014, 30(3):241-256.
21. Abbas A.S., Dehbi H.M., Ray K.K. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomised controlled cardiovascular outcome trials. Diabetes Obes Metab 2015, 18(3):295-299.
22. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015. Available at: . Accessed October 14, 2015. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm.
23. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170(14):1191-1201.
24. FDA approves Avandia (rosiglitzone) label update, lifts restriction on patient access. 2014. Available at: . Accessed October 15, 2015. http://us.gsk.com/en-us/media/press-releases/2014/fda-approves-avandia-rosiglitazone-label-update-lifts-restrictions-on-patient-access/.
25. Consoli A., Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. Diabetes Obes Metab 2013, 15(11):967-977.
26. Turner R.M., Kwok C.S., Chen-Turner C., et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014, 78(2):258-273.
27. Vivian E. Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes mellitus. Diabetes Educ 2015, 41(1 Suppl):5S-18S.
28. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, 373(22):2117-2128.
29. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
30. Trujillo J.M., Nuffer W., Ellis S.L. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015, 6(1):19-28.
31. Buse J.B., Bergenstal R.M., Glass L.C., et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154(2):103-112.
32. Rosenstock J., Fonseca V.A., Gross J.L., et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014, 37(8):2317-2325.
33. Marso S.P., Poulter N.R., Nissen S.E., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013, 166(5):823-830.e5.
34. Tibble C.A., Cavaiola T.S., Henry R.R. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes. Expert Rev Endocrinol Metab 2013, 8(3):247-259.
35. Ferdinand K.C., White W.B., Calhoun D.A., et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014, 64(4):731-737.
36. Karagiannis T., Liakos A., Bekiari E., et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2015, 17(11):1065-1074.
37. Paul S.K., Klein K., Maggs D., et al. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015, 14:10.
38. Prasad-Reddy L., Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 2015, 4:212283.
39. Li L., Shen J., Bala M.M., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014, 348:g2366.
40. Alves C., Batel-Marques F., Macedo A.F. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012, 98(2):271-284.
41. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2009.
42. Bydureon [package insert]. Wlimington, DE: AstraZeneca Pharmaceuticals; 2015.
43. Victoza [package insert]. Plainsboro, NJ: Novo Nordik; 2015.
44. Tanzeum [package insert]. Wilmington, DE: GlaxoSmithKline; 2015.
45. Trulicity [package insert]. Indianapolis, IN: Eli Lilly; 2014.
46. Rosenstock J., Sugimoto D., Strange P., et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006, 29(3):554-559.
47. Schwartz S., Sievers R., Strange P., et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003, 26(8):2238-2243.
48. Horvath K., Jeitler K., Berghold A., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, (2). CD005613.
49. Swinnen S.G., Simon A.C., Holleman F., et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, (7). CD006383.
50. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38(1):140-149.
51. American Diabetes Association (6) Glycemic targets. Diabetes Care 2015, 38(Suppl):S33-S40.
52. Vora J., Cariou B., Evans M., et al. Clinical use of insulin degludec. Diabetes Res Clin Pract 2015, 109(1):19-31.
53. Mannucci E., Monami M., Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009, 11:53-59.
54. Davidson M.B. Insulin analogs-is there a compelling case to use them? No!. Diabetes Care 2014, 37(6):1771-1774.
55. Lane W.S., Cochran E.K., Jackson J.A., et al. High-dose insulin therapy: is it time for U-500 insulin?. Endocr Pract 2009, 15(1):71-79.
56. Hood R.C., Arakaki R.F., Wysham C., et al. Two treatment approaches for human regular u-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose u-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract 2015, 21(7):782-793.
57. Scheen A.J. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013, 9(5):529-550.
58. Nogueira C., Souto S.B., Vinha E., et al. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones (Athens) 2013, 12(4):483-494.
59. Huang E.S., Liu J.Y., Moffet H.H., et al. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 2011, 34(6):1329-1336.
60. Bansal N., Dhaliwal R., Weinstock R.S. Management of diabetes in the elderly. Med Clin North Am 2015, 99(2):351-377.
61. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
62. American Diabetes Association (8) Cardiovascular disease and risk management. Diabetes Care 2015, 38(Suppl):S49-S57.
63. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2889-2934.